CSF1R-IN-17

• UNSPSC Description:

  CSF1R-IN-17 (compound 9) is a potent and selective CSF1R antagonist, with an IC50 of 0.2 nM. CSF1R-IN-17 can inhibit osteoclast differentiation[1].

• Target Antigen:

  c-Fms

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/csf1r-in-17.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OCCC1=CC=C(C2=NC3=C(N(C)CC4CCOCC4)N=CN=C3N2)C=C1

• Molecular Weight:

  367.44

• References & Citations:

  [1]Aarhus TI, et, al. A highly selective purine-based inhibitor of CSF1R potently inhibits osteoclast differentiation. Eur J Med Chem. 2023 Jul 5;255:115344.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported